189094-06-2

Usage

Uses

Used in Pharmaceutical Research and Development:
TBE-THIQ is utilized as a key intermediate in the synthesis of various organic molecules and pharmaceuticals, particularly those targeting neurological disorders. Its unique chiral structure allows for the creation of enantiomer-specific drugs, which can have different therapeutic effects and reduce potential side effects.
Used in the Treatment of Neurological Disorders:
In the field of neurology, TBE-THIQ is employed as a potential therapeutic agent for the treatment of Parkinson's disease and other related neurological conditions. Its application in this area is due to its ability to modulate specific biological pathways and receptors implicated in these disorders, offering a promising avenue for the development of more effective treatments.
Used in Organic Synthesis:
TBE-THIQ serves as a versatile precursor in organic synthesis, enabling the creation of a wide range of chemical compounds. Its reactivity and structural features make it a valuable component in the synthesis of complex organic molecules, contributing to advancements in various chemical and pharmaceutical applications.

Upstream product

• 74163-81-8 L-Tic-OH 
• 115-11-7 isobutene 
• 77497-95-1 (3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride 
• 103733-65-9 (3R)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
• 81477-94-3 N-(diphenylmethylene)glycine tert-butyl ester 
• 91-13-4 α,α'-dibromo-o-xylene 
• 82586-60-5 (S)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, 1,1-dimethylethyl ester, hydrochloride 
• 79276-06-5 THIQ tert-butyl ester PTSA salt 
• 79276-05-4 Z-Tic-OtBu 
• 79261-58-8 (S)-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylic acid 2-benzyl ester 

Relevant academic research and scientific papers

Continuous Flow Synthesis of ACE Inhibitors From N-Substituted l-Alanine Derivatives

A strategy for the continuous flow synthesis of angiotensin converting enzyme (ACE) inhibitors is described. An optimization effort guided by in situ IR analysis resulted in a general amide coupling approach facilitated by N-carboxyanhydride (NCA) activation that was further characterized by reaction kinetics analysis in batch. The three-step continuous process was demonstrated by synthesizing 8 different ACE inhibitors in up to 88 % yield with throughputs in the range of ≈0.5 g h?1, all while avoiding both isolation of reactive intermediates and process intensive reaction conditions. The process was further developed by preparing enalapril, a World Health Organization (WHO) essential medicine, in an industrially relevant flow platform that scaled throughput to ≈1 g h?1.

PREPARATION OF QUINAPRIL HYDROCHLORIDE

Methods and materials for preparing quinapril, its pharmaceutically acceptable salts, including quinapril hydrochloride, are disclosed. The method includes reacting (2S,4S)-2-(4-methyl-2,5-dioxo-oxazolidin-3-yl)-4-phenyl-butyric acid ethyl ester with (3S)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid tert-butyl ester to yield quinapril tert-butyl ester, which is subsequently reacted with an acid to yield quinapril or an acid addition salt of quinapril.

Concise, catalytic asymmetric synthesis of tetrahydroisoquinoline- and dihydroisoquinoline-3-carboxylic acid derivatives

Catalytic asymmetric synthesis of tetrahydroisoquinoline-3-carboxylic acid (Tic) derivatives 1 has been accomplished by the successful utilization of phase-transfer catalysis of the C2-symmetric chiral quaternary ammonium bromides. Our approach also enables facile synthesis of quaternary isoquinoline derivatives 2 and 3 with high enantiomeric purities.

Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary δ opioid antagonist activity

The δ opioid antagonist H-Dmt-Tic-OH (2',6'-dimethyl-L-tyrosyl-1,2,3,4- tetrahydroisoquinoline-3-carboxylic acid) exhibits extraordinary δ receptor binding characteristics [K(i)(δ) = 0.022 nM; K(i)(μ)/K(i)(δ) = 150 000] and δ antagonism (pA2 = 8.2; Ke = 5.7 nM). A change in chirality of Dmt at Cα (1, 2, 6, 8, 10, 13) curtailed δ receptor parameters, while replacement of its α-amino function by a methyl group (3) led to inactivity; Tyr-Tic analogues 4 and 11 weakly interacted with δ receptors. N-Alkylation of H- Dmt-Tic-OH and H-Dmt-Tic-Ala-OH with methyl groups produced potent δ-opioid ligands with high δ receptor binding capabilities and enhanced δ antagonism: (i) N-Me-Dmt-Tic-OH 5 had high δ opioid binding (K(i)(δ) = 0.2 nM), elevated δ antagonism on mouse vas deferens (MVD) (pA2 = 8.5; K(e) = 2.8 nM), and nondetectable μ activity with guinea pig ileum (GPI). (ii) N,N- Me2-Dmt-Tic-OH (12) was equally efficacious in δ receptor binding (K(i)(δ) = 0.12 nM; K(i)(μ)/K(i)(δ) = 20 000), but δ antagonism rose considerably (pA2 = 9.4; K(e) = 0.28 nM) with weak μ antagonism (pA2 = 5.8; K(e) = 1.58 μM; GPI/MVD = 1:5640). N-Me-(9) and N,N-Me2-Dmt-Tic-Ala-OH (15) also augmented δ opioid receptor binding, such that 15 demonstrated high affinity (K(i)(δ) = 0.0755 nM) and selectivity (K(i)(μ)/K(i)(δ) = 20 132) with exceptional antagonist activity on MVD (pA2 = 9.6; K(e) = 0.22 nM) and weak antagonism on GPI (pA2 = 5.8; K(e) = 1.58 μM; GPI/MVD = 1:7180). Although the amidated dimethylated dipeptide analogue 14 had high K(i)(δ) (0.31 nM) and excellent antagonist activity (pA2 = 9.9; K(e) = 0.12 nM), the increased activity toward μ receptors in the absence of a free acid function at the C- terminus revealed modest δ selectivity (K(i)(μ)/KK(i)(δ) = 1 655) and somewhat comparable bioactivity (GPI/MVD = 4500). Thus, the data demonstrate that N,N-(Me)2-Dmt-Tic-OH (12) and N,NMe2-Dmt-Tic-Ala-OH (15) retained high δ receptor affinities and δ selectivities and acquired enhanced potency in pharmacological bioassays on MVD greater than that of other peptide or non- peptide δ antagonists.

Studies on angiotensin-converting enzyme inhibitors. I. Syntheses and angiotensin-converting enzyme inhibitory activity of 2-(3-merecaptopropionyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives

(3S)-2-[(2S)-mercapto-2-methylpropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [(3S), (2S)-6a] was prepared by the reaction of (3S)-1,2,3,4-tetrahydreoisoquinoline-3-carboxylic acid test-butyl ester [(3S)-2a) or benzyl ester [(3S)-2b] with 3-benzoylthio-2-methylpropionyl chloride (3a), followed by fractional crystallization and removal of the protective group. The absolute configuration of (3S), (2S)-6a was confirmed by X-ray diffraction analysis of the thiazepinol[4,3-b]isoquinoline compound (7) derived from 6a. Resolution of 3-benzoylthio-2-methylpropionic acid (8) was completed by using optically active phenylalanine amide as a resolving agent. The other optical isomers of (3S),(2S)-6a were prepared by the reaction of (3S)- or (3R)-2b with optically active 3a. The in vitro ACE inhibitory activity of each isomer of 6a was evaluated. Among them, (3S),(2S)-6a was found to be the most potent inhibitor with an IC50 value of 8.6X10-9M. Compound (3S),(2S)-6a induced a dose-dependent inhibition of the pressor response to angiotensin 1 after oral administration to normotensive anesthetized rats. Moreover, (3S),(2S)-6a markedly reduced the systolic blood pressure in renal hypertensive rats (RHR) and spontaneously hypertensive rats (SHR). The in vivo ACE inhibitory activity and the hypotensive effects of (3S),(2S)-6a were comparable to those of captopril.